• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Large owner Poplar Point Capital Partners Lp bought $29,858 worth of shares (48,930 units at $0.61) (SEC Form 4)

    4/15/25 12:22:43 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NBY alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    POPLAR POINT CAPITAL PARTNERS LP

    (Last) (First) (Middle)
    330 PRIMROSE ROAD, SUITE 400

    (Street)
    BURLINGAME CA 94010

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    NovaBay Pharmaceuticals, Inc. [ NBY ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    02/25/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock, par value $0.01 per share 02/25/2025 P 25,033 A $0.6199 730,205 D(1)
    Common Stock, par value $0.01 per share 02/26/2025 P 6,302 A $0.61 736,507 D(1)
    Common Stock, par value $0.01 per share 02/27/2025 P 385 A $0.61 736,892 D(1)
    Common Stock, par value $0.01 per share 02/28/2025 P 13,108 A $0.602 750,000 D(1)
    Common Stock, par value $0.01 per share 03/04/2025 P 4,000 A $0.5784 754,000 D(1)
    Common Stock, par value $0.01 per share 03/07/2025 P 102 A $0.55 754,102 D(1)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    POPLAR POINT CAPITAL PARTNERS LP

    (Last) (First) (Middle)
    330 PRIMROSE ROAD, SUITE 400

    (Street)
    BURLINGAME CA 94010

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    POPLAR POINT CAPITAL MANAGEMENT LLC

    (Last) (First) (Middle)
    330 PRIMROSE ROAD, SUITE 400

    (Street)
    BURLINGAME CA 94010

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    POPLAR POINT CAPITAL GP LLC

    (Last) (First) (Middle)
    330 PRIMROSE ROAD, SUITE 400

    (Street)
    BURLINGAME CA 94010

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    FAKHRY JAD

    (Last) (First) (Middle)
    330 PRIMROSE ROAD, SUITE 400

    (Street)
    BURLINGAME CA 94010

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    1. This Form 4 is being jointly filed by Poplar Point Capital Partners LP ("PPCP"), Poplar Point Capital Management LLC ("PPCM"), Poplar Point Capital GP LLC ("PPCGP"), and Mr. Jad Fakhry (collectively with PPCP, PPCM and PPCGP, the "Reporting Persons") with respect to shares of common stock of the above named issuer owned by PPCP. PPCM is the investment manager of PPCP. PPCGP is the general partner of PPCP. Mr. Fakhry is the manager of PPCM and PPCGP, and owns a controlling interest in, PPCM and PPCGP. The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).
    /s/ Jad Fakhry, as authorized person for Joint Reporting Persons 04/14/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NBY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NBY

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NBY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Poplar Point Capital Partners Lp bought $15,967 worth of shares (28,731 units at $0.56) (SEC Form 4)

      4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

      4/15/25 12:50:08 PM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Poplar Point Capital Partners Lp bought $74,519 worth of shares (123,365 units at $0.60) (SEC Form 4)

      4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

      4/15/25 12:46:27 PM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Poplar Point Capital Partners Lp bought $30,718 worth of shares (49,927 units at $0.62) (SEC Form 4)

      4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

      4/15/25 12:40:59 PM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBY
    SEC Filings

    See more
    • NovaBay Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)

      4/22/25 5:02:17 PM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by NovaBay Pharmaceuticals Inc.

      10-K - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)

      4/2/25 5:17:25 PM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-K filed by NovaBay Pharmaceuticals Inc.

      NT 10-K - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)

      3/31/25 7:01:35 PM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Poplar Point Capital Partners Lp bought $15,967 worth of shares (28,731 units at $0.56) (SEC Form 4)

      4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

      4/15/25 12:50:08 PM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Poplar Point Capital Partners Lp bought $74,519 worth of shares (123,365 units at $0.60) (SEC Form 4)

      4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

      4/15/25 12:46:27 PM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Poplar Point Capital Partners Lp bought $30,718 worth of shares (49,927 units at $0.62) (SEC Form 4)

      4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

      4/15/25 12:40:59 PM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NovaBay Pharmaceuticals to Hold Special Meeting of Stockholders

      Stockholders as of the March 18, 2025 record date will be entitled to vote Company engages financial advisor to explore strategic options should stockholders fail to approve the dissolution proposal NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces it will hold a virtual Special Meeting on April 16, 2025, at which stockholders will vote on a proposal for the liquidation and dissolution of the Company under Delaware law, pursuant to the Plan of Complete Liquidation and Dissolution of the Company (the "Dissolution"). The Special Meeting was announced in a preliminary proxy statement on Schedule 14A filed with the Securities and Exchange Commission ("SEC") on F

      3/7/25 6:50:00 AM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NovaBay Pharmaceuticals Completes the Sale of its Eyecare Business to PRN and Further Adjourns its Special Meeting of Stockholders on Dissolution Proposal

      Stockholders voted to unlock the value of NovaBay's Avenova® eyecare business by approving the $11.5 million asset sale Reconvened Special Meeting adjourned to allow additional time for votes to reach the 50% threshold of outstanding common stock in favor of Proposal Two, providing for the Dissolution of the Company Stockholders who have not yet voted are strongly encouraged to vote FOR Proposal Two at the Special Meeting scheduled to reconvene on January 30, 2025 NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces the completion of the sale of its Avenova eyecare business and related assets to PRN Physician Recommended Nutriceuticals, LLC ("PRN") for $11.

      1/23/25 8:00:00 AM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders

      Reconvened meeting adjourned due to insufficient votes to reach the 50% threshold of outstanding common shares voting in favor of Proposal One and Proposal Two Stockholders who have not voted are strongly encouraged to vote FOR Proposal One and FOR Proposal Two at the Special Meeting to reconvene on January 16, 2025 NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces that its Reconvened Special Meeting of Stockholders held on December 18, 2024 has been adjourned until January 16, 2025 at 11:00 a.m. Pacific time to provide stockholders additional time to vote on Proposal One and Proposal Two. Both proposals received significant support based on the shares tha

      12/19/24 6:50:00 AM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by NovaBay Pharmaceuticals Inc.

      SC 13G/A - NovaBay Pharmaceuticals, Inc. (0001389545) (Subject)

      11/8/24 5:31:40 PM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by NovaBay Pharmaceuticals Inc. (Amendment)

      SC 13G/A - NovaBay Pharmaceuticals, Inc. (0001389545) (Subject)

      2/14/24 2:52:33 PM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by NovaBay Pharmaceuticals Inc. (Amendment)

      SC 13G/A - NovaBay Pharmaceuticals, Inc. (0001389545) (Subject)

      2/13/24 5:17:39 PM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBY
    Financials

    Live finance-specific insights

    See more
    • NovaBay Pharmaceuticals to Hold Second Quarter 2024 Conference Call on August 13, 2024

      NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three and six months ended June 30, 2024 after market close on Tuesday, August 13, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Tuesday, August 13, 4:30 p.m. ET / 1:30 p.m. PT   Pre-Registration: Participants can pre-register for the conference call here:   Callers who pre-register will be emailed conference details and unique Registration ID to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and

      8/1/24 6:50:00 AM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NovaBay Pharmaceuticals Reports First Quarter 2024 Financial Results

      Net product sales increased 13% over the prior year driven by higher sales of Avenova®-branded products through OTC channels and branded wound care products Sales and marketing expenses declined 15% reflecting continued digital marketing optimization Ordered product sales for Avenova-branded products on Amazon.com reached new all-time records in March and April Conference call begins at 4:30 p.m. Eastern time today NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) reports financial results for the three months ended March 31, 2024 and provides a business update. "Net product sales growth of 13% versus the prior year was driven by higher sales of Avenova-branded products through online

      5/9/24 4:05:00 PM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024

      NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three months ended March 31, 2024 after market close on Thursday, May 9, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time:  Thursday, May 9, 4:30 p.m. ET / 1:30 p.m. PT   Pre-Registration: Participants can pre-register for the conference call here:   Callers who pre-register will be emailed conference details and unique Registration ID to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.

      5/3/24 6:50:00 AM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBY
    Leadership Updates

    Live Leadership Updates

    See more
    • Innovations in Disinfection Technology Aid the Return of Workers

      NEW YORK, Dec. 9, 2020 /PRNewswire/ -- The current pandemic has been devastating for the global economy and has caused severe backlogs in hospitals. Additionally, a spike in demand for Personal Protective Equipment (PPE) and new disinfecting technologies has also been seen. For example, when it comes for PPE, the global market was valued at USD 52.7 Billion in 2019 and is expected to reach USD 92.5 Billion by 2025 while growing at a CAGR of 8.7% during 2020-2025, according to VynZ Research. As for new technologies for disinfection, a recent example comes from LG Electronics, which announced on Wednesday the launch of a disinfection robot that will assist in containing the spread of the vi

      12/9/20 9:00:00 AM ET
      $NBY
      $CEMI
      $BSGM
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Biotechnology: Electromedical & Electrotherapeutic Apparatus